Panelists discuss how managing common adverse events associated with tyrosine kinase inhibitors (TKIs) such as nilotinib requires proactive strategies including supportive medications, dose ...

Panelists discuss how simpler treatment regimens with fewer restrictions, such as the new nilotinib formulation without ...

The FDA approved larotrectinib for use in adult and pediatric patients with NTRK fusion-positive solid tumors with few other options.

T-DXd followed by THP improved pCR in high-risk, early-stage HER2+ breast cancer in the phase 3 DESTINY-Breast11 trial.

ADRX-0706 has received FDA fast track designation for the treatment of metastatic or locally advanced squamous cell cervical ...

home / morning-rounds / treatment-strategies-in-esr1-mut-er-her2-breast-cancer-practical-insights-for-optimal-outcomes ...

Treatment-related adverse effects were reported in 97.2% of heavily pretreated patients with uterine serous carcinoma taking ...

Infusion bays designed with nurse input provide patients the choice between privacy and community while allowing support from loved ones.

Infusion bays designed with nurse input provide patients the choice between privacy and community while allowing support from loved ones.